Clinical Trial Update: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA [Phase 4]

View source ↗

Summary

Phase 4 trial update describing strategies for managing infusion-associated reactions in relapsing-remitting multiple sclerosis patients treated with Lemtrada (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED